Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and ...

First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer ...

Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

Delray Medical Center cut the ribbon on its newest high-tech machine last week that targets brain areas to treat movement ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

Researchers have developed a flexible, biodegradable electrode capable of stimulating neural precursor cells (NPCs) in the ...